Biotechnology companies are developing novel obesity medicines to compete with blockbuster weight-loss drugs.

In January 2023, the world was abuzz with stories of a revolutionary weight-loss drug – a simple, self-administered injection ...

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...

PGC-1α research offers new hope for weight loss by boosting metabolic efficiency and providing accessible management ...

The second largest decline had been the previous year, 2023, meaning that in each of the last two years the country’s most ...

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs for obesity and diabetes.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Polls provide a useful window into understanding how Americans view their own weight and the recent availability of drugs ...

If innovative cancer therapies were the top launches to watch in 2024, this year’s high-profile biopharma debuts is slated to ...

Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...

The U.S. FDA has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea.

Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...